MATINS Trial in Cell Reports Medicine
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine - Bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumors - CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects - Bexmarilimab induced macrophage activation and increased IFNɣ signaling in patients who achieved disease control and prolonged survival